JP2002531517A - 異所性石灰化を阻害する方法 - Google Patents

異所性石灰化を阻害する方法

Info

Publication number
JP2002531517A
JP2002531517A JP2000586355A JP2000586355A JP2002531517A JP 2002531517 A JP2002531517 A JP 2002531517A JP 2000586355 A JP2000586355 A JP 2000586355A JP 2000586355 A JP2000586355 A JP 2000586355A JP 2002531517 A JP2002531517 A JP 2002531517A
Authority
JP
Japan
Prior art keywords
osteopontin
ectopic calcification
calcification
cells
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000586355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531517A5 (https=
Inventor
セシリア エム． ギアチェリ，
スージー スタイツ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2002531517A publication Critical patent/JP2002531517A/ja
Publication of JP2002531517A5 publication Critical patent/JP2002531517A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2000586355A 1998-12-07 1999-12-07 異所性石灰化を阻害する方法 Pending JP2002531517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/206,576 US6551990B2 (en) 1998-12-07 1998-12-07 Methods of inhibiting ectopic calcification
US09/206,576 1998-12-07
PCT/US1999/029173 WO2000033865A1 (en) 1998-12-07 1999-12-07 Methods of inhibiting ectopic calcification

Publications (2)

Publication Number Publication Date
JP2002531517A true JP2002531517A (ja) 2002-09-24
JP2002531517A5 JP2002531517A5 (https=) 2006-12-14

Family

ID=22766997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586355A Pending JP2002531517A (ja) 1998-12-07 1999-12-07 異所性石灰化を阻害する方法

Country Status (6)

Country Link
US (2) US6551990B2 (https=)
EP (1) EP1135155A1 (https=)
JP (1) JP2002531517A (https=)
AU (1) AU769806B2 (https=)
CA (1) CA2354189A1 (https=)
WO (1) WO2000033865A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501136A (ja) * 2005-06-10 2009-01-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
JP2009216567A (ja) * 2008-03-11 2009-09-24 Hokkaido Univ ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
US7678889B2 (en) 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
JP2014533681A (ja) * 2011-11-17 2014-12-15 ネンキ インスティチュート オブ エクスペリメンタル バイオロジー 神経膠腫を治療するための組成物および方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295010A1 (en) * 2000-08-18 2002-03-04 Case Western Reserve University Regulator gene and system useful for the diagnosis and therapy of osteoporosis
AU2003239589A1 (en) * 2002-05-24 2003-12-12 Schering-Plough Ltd. Eta-1 gene and methods for use
CA2547654C (en) * 2003-12-01 2012-09-25 Arla Foods Amba Use of osteopontin in dental formulations
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
US7167746B2 (en) 2004-07-12 2007-01-23 Ats Medical, Inc. Anti-coagulation and demineralization system for conductive medical devices
US20060276534A1 (en) * 2005-03-17 2006-12-07 Amgen Inc. Methods of decreasing calcification
US7463758B2 (en) * 2005-06-02 2008-12-09 Nordio Bioscience A/S Method of deriving a quantitative measure of a degree of calcification of an aorta
US7561727B2 (en) * 2005-06-02 2009-07-14 Nordic Bioscience Imaging A/S Method of deriving a quantitative measure of a degree of calcification of an aorta
US20070005213A1 (en) * 2005-06-30 2007-01-04 Hyundai Autonet Co., Ltd. Backward control for automobiles using telematics and method thereof
US20070134229A1 (en) * 2005-10-11 2007-06-14 Bin Tian Non-native constitutively active osteopontin
AU2006304778B2 (en) * 2005-10-21 2011-04-28 Amgen Inc. Methods of decreasing vascular calcification using IL-1 inhibitors
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
AU2008223817A1 (en) * 2007-03-02 2008-09-12 National University Of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
WO2008137281A1 (en) * 2007-05-03 2008-11-13 Fox Chase Cancer Center Compositions and methods for altering pancreas or liver function
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
WO2014071128A1 (en) * 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Macrophage-derived matrix vesicles: an alternative mechanism for microcalcification in atherosclerotic plaques
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
DK3618845T3 (da) 2017-05-04 2021-04-19 Follicum Ab Peptider til behandling af diabetes
CN109557309B (zh) * 2018-12-04 2021-09-10 九江学院附属医院 碳酸酐酶-2作为检测标记物在肾结石诊断方面的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001350A (en) * 1987-12-11 1999-12-14 Somatix Therapy Corp Genetic modification of endothelial cells
US5340934A (en) * 1989-11-03 1994-08-23 The United States Of Americas As Represented By The Secretary Of Health & Human Services CDNA sequences of human bone matrix proteins
US5304496A (en) 1991-06-10 1994-04-19 Children's Hospital Of Philadelphia Biological regulation of mineralization
WO1994025584A1 (en) * 1993-04-28 1994-11-10 Johns Hopkins University School Of Medicine Chronic endothelial cell culture under flow
US5824651A (en) 1993-05-10 1998-10-20 Universite De Montreal Process for modification of implant surface with bioactive conjugates for improved integration
US5695761A (en) 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678889B2 (en) 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
JP2009501136A (ja) * 2005-06-10 2009-01-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
JP2009216567A (ja) * 2008-03-11 2009-09-24 Hokkaido Univ ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
JP2014533681A (ja) * 2011-11-17 2014-12-15 ネンキ インスティチュート オブ エクスペリメンタル バイオロジー 神経膠腫を治療するための組成物および方法

Also Published As

Publication number Publication date
AU2478300A (en) 2000-06-26
WO2000033865A9 (en) 2002-08-22
WO2000033865A1 (en) 2000-06-15
US20030158113A1 (en) 2003-08-21
CA2354189A1 (en) 2000-06-15
WO2000033865A8 (en) 2003-11-06
US20020032157A1 (en) 2002-03-14
AU769806B2 (en) 2004-02-05
EP1135155A1 (en) 2001-09-26
US7419950B2 (en) 2008-09-02
US6551990B2 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
US7419950B2 (en) Methods of inhibiting ectopic calcification
JP2002531517A5 (https=)
JP3693338B2 (ja) 組織形成因子誘導による炎症反応の調節
Yoneda et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Gray et al. FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia
EP0308386B1 (en) New medical use
US5958411A (en) Methods of inhibiting ECM accumulation in the CNS by inhibition of TGF-β
Brodkey et al. The complex nature of interactive neuroregeneration-related molecules
JP3973050B2 (ja) モルフォゲン誘発性肝再生
Xiang et al. The impact of sitagliptin on macrophage polarity and angiogenesis in the osteointegration of titanium implants in type 2 diabetes
US7060680B2 (en) Morphogen treatments for limiting proliferation of epithelial cells
US20120125348A1 (en) Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
US5155038A (en) Use of thrombospondin to promote wound healing
JP2007130027A (ja) 星状細胞の増殖の誘導方法およびそのための組成物
JP5400006B2 (ja) 虚血性疾患の予防または治療剤
Birinyi et al. Observations on human smooth muscle cell cultures from hyperplastic lesions of prosthetic bypass grafts: Production of a platelet-derived growth factor—like mitogen and expression of a gene for a platelet-derived growth factor receptor—A preliminary study
EP2310035B1 (en) Fibroblast growth factor (fgf) analogs and uses thereof
JPH06172207A (ja) 肺傷害治療剤
Schultze‐Mosgau et al. Transforming growth factor‐β receptor‐II up‐regulation during wound healing in previously irradiated graft beds in vivo
US6413931B1 (en) Peptide inhibitor of fibrinogen blood clotting
CN120518713B (zh) 一种抗血栓多肽Cb17037及其应用
JP2008516629A (ja) 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価
US11161887B2 (en) Uromodulin for use in prevention and therapy of pathological crystallization
Atria Understanding the Role of Skeletal Stem Cells in Load-Induced Bone Formation, Bone Repair, and Their Relationship With Angiogenesis
JP2024046128A (ja) 骨形成促進剤

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100614